Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.240
0.00 (0.00%)
At close: Oct 2, 2026, 4:00 PM EDT
2.200
-0.040 (-1.79%)
After-hours: Oct 2, 2026, 7:30 PM EDT
Xenetic Biosciences Employees
Xenetic Biosciences had 2 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$1,630,389
Profits / Employee
-$1,237,547
Market Cap
5.25M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2024 | 2 | -2 | -50.00% | 2 | 0 |
| Dec 31, 2023 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2022 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2021 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AIM ImmunoTech | 21 |
| Cardio Diagnostics Holdings | 17 |
| Processa Pharmaceuticals | 12 |
| NuCana | 12 |
| Ernexa Therapeutics | 7 |
| Lexaria Bioscience | 7 |
| Kairos Pharma | 4 |
| Creative Medical Technology Holdings | 4 |
XBIO News
- 17 days ago - Xenetic Biosciences Transcript: M&A announcement - Transcripts
- 17 days ago - Xenetic Biosciences Press release: M&A announcement - Filings
- 17 days ago - Xenetic Biosciences Slides: M&A announcement - Filings
- 17 days ago - Xenetic, Santerus enter definitive share exchange agreement - TheFly
- 17 days ago - Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics - Accesswire
- 18 days ago - Xenetic Biosciences Slides: Investor presentation - Filings
- 1 month ago - Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform - Accesswire
- 1 month ago - Xenetic Biosciences Quarterly report: Q2 2026 - Filings